Spero Therapeutics to Present at Investor Conferences in March
February 25 2021 - 8:30AM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing treatments in high unmet need areas
involving multi-drug resistant bacterial infections and rare
diseases, today announced that Ankit Mahadevia, M.D.,
President and Chief Executive Officer of Spero Therapeutics,
will present at the following investor conferences in March
2021:
The Cowen 41st Annual Healthcare
ConferencePanel Name: Respiratory and Infections
PanelPanel Presentation Date and Time: Monday, March 1st at
10:20 – 11:20 AM EST
Oppenheimer 31st Annual Healthcare
ConferenceCorporate Presentation Date and Time: Tuesday,
March 16th at 10:00 – 10:30 AM EST
Webcasts of corporate presentations may be
accessed through Spero Therapeutics’ website
(www.sperotherapeutics.com) on the “Events and Presentations” page
under the “Investors and Media” tab. Replays of corporate
presentations will be archived on the website for 90 days following
the conclusion of each event.
About Spero TherapeuticsSpero
Therapeutics, Inc. is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug-resistant (MDR)
bacterial infections and rare diseases.
Spero’s lead product candidate, tebipenem HBr
(tebipenem pivoxil hydrobromide; formerly SPR994), is being
developed as the first oral carbapenem antibiotic for use in
complicated urinary tract infections (cUTI) and acute
pyelonephritis (AP). In September 2020, Spero announced
positive top-line results from its Phase 3 ADAPT-PO clinical trial
of tebipenem HBr in cUTI and AP.
Spero is also developing SPR720, its novel oral
therapy product candidate being developed for the treatment of
rare, orphan pulmonary disease caused by non-tuberculous
mycobacterial (NTM) infections.
Spero also has an IV-administered next
generation polymyxin product candidate, SPR206, developed from its
potentiator platform that is being developed to treat MDR
Gram-negative infections in the hospital setting.
For more information,
visit https://sperotherapeutics.com.
Spero Investor and Media
Contact:Sharon KlahreVice President, Investor
Relations857-242-1547IR@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2023 to Apr 2024